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RESEARCH ON METHODS – Study Design 
 
PRM209  
HOW ARE CENTRES INCLUDED IN RANDOMISED CONTROLLED TRIALS WITH 
PARALLEL ECONOMIC EVALUATIONS IN THE UK?  
Gheorghe A, Roberts TE, Fletcher BR, Calvert M 
University of Birmingham, Birmingham, UK  
OBJECTIVES: The sample of centres participating in randomised controlled trials 
(RCTs) may affect the generalisability of economic evaluation results if it is 
biased, but there is limited evidence on how trialists currently include centres in 
RCTs. Our aim was to investigate the reported rationales for centre selection in 
RCTs with parallel economic evaluations in the UK. METHODS: We 
systematically reviewed and meta-summarised centre selection information in 
full-length protocols of RCTs with parallel economic evaluations funded by the 
UK National Institute of Health Research – Health Technology Assessment 
programme (NIHR-HTA) and initiated between January 2005 and January 2012. 
Free text information on centre selection was extracted, abstracted and 
categorised; effect sizes (%) were calculated for the emerging categories as a 
measure of prevalence relative to the number of included studies. RESULTS: Of 
365 reviewed studies, 129 trial protocols were included in the systematic review 
with a total target sample size of 317,000 participants. The meta-summary 
identified 53 centre selection considerations, grouped under three categories: 
diversity and representativeness, centre characteristics and trial participation. A 
total of 78 (60%) protocols provided a rationale for centre selection. A total of 31 
(24%) protocols explicitly considered representativeness, for example in terms of 
the target population (11%) and delivered services (12%). Fifty-seven (44%) 
protocols required particular centre characteristics, such as size (17%) and 
research experience (15%). Thirty-seven (29%) protocols envisaged 
considerations that would ensure successful trial participation, such as the 
willingness to participate (7%) and ensuring recruitment (13%). CONCLUSIONS: 
The rationale for centre selection in RCTs with parallel economic evaluations is 
currently underreported in trial protocols. Centres are primarily enrolled on 
pragmatic grounds and less so with a view to ensuring generalisability. There are 
little reasons to believe that economic results from RCTs are informed by a 
representative sample of centres, thus questioning the representativeness of 
their findings.  
 
PRM210  
RECRUITING PATIENTS WITH A RARE BLOOD DISORDER AND THEIR 
CAREGIVERS THROUGH SOCIAL MEDIA  
DiBenedetti DB1, Coles TM1, Sharma T2 
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novo Nordisk A/S, Søborg, Denmark  
OBJECTIVES: Recruiting research participants with experiences relevant to rare 
diseases (patients and caregivers) remains a constant challenge. Researchers often 
rely on patient advocacy or support groups as well as clinician referrals, which each 
present unique recruitment issues. Social media sites, such as Facebook, can 
potentially be helpful in recruiting patients for many study types, particularly those 
involving hard-to-reach populations. However, little is known about the value of 
social media in recruiting populations with rare medical conditions. In this study, 
Facebook was used to recruit adult patients and parents of children with 
hemophilia A for participation in a Web-based survey. METHODS: A cross-sectional 
study was developed to better understand patient and caregiver experiences and 
behaviors associated with treatments for hemophilia A. Members of three local or 
national blood disorder organizations in the United States and Canada were invited 
to complete a Web-based survey via postings on each organizations' Web site 
and/or e-mail invitations sent to each organizations' member lists. Additionally, 
two organizations posted advertisements about the study on their respective 
Facebook pages. A nominal donation was made to each organization for their 
assistance in study recruitment. RESULTS: Of the 145 individuals who responded to 
survey invitations, 101 (70%) completed the survey questionnaire. More than half 
(58%) of the completed questionnaires were from respondents recruited through 
Facebook who were a mean age of 35.8 years (SD = 8.3), similar to those recruited 
through more standard methods. The organization that did not post a study 
advertisement on Facebook recruited the fewest participants (only 13% of the total 
respondents). CONCLUSIONS: This real-world study emphasizes the assistance and 
value of social media in study recruitment. Use of social media in recruiting can be 
an efficient means of reaching large numbers of potential respondents.  
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THE EFFECTS OF EXCLUDING TREATMENTS FROM NETWORK META-ANALYSIS  
Mills E1, Kanters S2, Thorlund K1 
1Stanford University, Palo Alto, CA, USA, 2University of British Columbia, Vancouver, BC, 
Canada  
OBJECTIVES: To investigate the effect of omitting treatments from network 
meta-analyses on overall treatment effects and treatment rankings. METHODS: 
We selected published network meta-analyses that met the following criteria: 
compared t≥5 treatments, had ≥2 loops, ≥2tstudies and set to determine 
treatment superiority. If multiple published analyses considered the same 
treatments (e.g. multiple networks pertaining to COPD drugs), the larger network 
was selected. We defined a node’s connectivity as its number of edges. Each 
network was analyzed systematically with the removal of one node at a time. 
Nodes that were in ≥50% of studies were not removed. Impact of node exclusion 
was measured using the relative change in treatment effect estimates, changes 
in the top-three ranked treatments, and changes in probabilities of being the 
best treatment. Relative changes in effect size were expressed as fold-deviations. 
For each network with excluded node(s), we measured the maximum and 
geometric mean of fold-changes. RESULTS: In total, 19 networks were selected 
for analysis. Approximately half the networks had average fold-change larger 
than 1.10 (greater than 10% relative change in treatment effects). Approximately 
half of the networks also had changes in the top three ranks and substantial 
changes in treatment rank probabilities. Within these networks, the maximum 
fold-change was generally larger than 1.25. In networks with no changes in top-
three ranked treatments, the ‘best’ treatment mostly had probability ≥70% of 
being the best. Two features were consistent across the nodes leading to the 
largest change in probabilities and effects: they were among the most connected 
nodes and tended to have a 0% probability of being the best treatment. 
CONCLUSIONS: Network meta-analytic methods are still in their infancy. Our 
results suggest that failing to include one or more treatments within a network 
can lead to important changes in conclusions reached.  
 
PRM212  
USING AN ONLINE DATA ANALYTIC TOOL TO INFORM STUDY DESIGNS FOR 
CHRONIC DISEASE POPULATIONS: A CASE STUDY WITH CLL  
Foley K1, Hansen LG2 
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Northwood, NH, USA  
OBJECTIVES: Chronic lymphocytic leukemia (CLL) accounts for almost 40% of all 
leukemias. Current treatments have high rates of adverse events requiring 
hospitalization. With promising treatments on the horizon, the need for well-
designed studies of treatment patterns and adverse events will increase. 
Designing studies can be challenging given the long-term nature of CLL. This 
study uses an online analytic tool to explore the necessary observation period to 
accurately assess treatment and hospitalization rates. METHODS: Using the 
Treatment Pathways tool and data from an 8-year oncology subset of the 2004 – 
2012 MarketScan®databases, we identified patients with two plus claims for CLL, 
one year prior enrollment, no prior treatment. Four follow-up groups were 
assessed: 1, 2, 3, and 4 years of continuous enrollment (CE). For each CE, we 
identified patients treated with bendamustine (B), or fludarabine, rituximab, 
and/or cyclophosphamide (F/R/C). Treatment and hospitalization rates and the 
time between diagnosis, treatment, and hospitalization were calculated. 
RESULTS: A total of 4886 patients met all inclusion criteria; 3348 had 1 year, 2201 
had 2 years, 1451 had 3 years, and 874 had 4 years CE. Bendamustine use 
increased from 4% among those with 1 year CE to 5% for all other CE groups. 
F/R/C use increased from 21% among those with 1 year to 27% among those with 
4 years CE. Hospitalization rates increased from 41% to 49% for bendamustine, 
and 38% to 44% for F/C/R from 1 year to 4 years CE. Among those with 4 yrs CE, 
median time to first treatment was 4.3 years for bendamustine, 1.4 years for 
F/C/R; median time to first hospitalization was 96 and 365 days, respectively. 
CONCLUSIONS: This study used an online tool to quickly assess the impact of 
various CE criteria. The data demonstrate how shorter CE underestimates 




USING REAL-WORLD CLAIMS DATA FOR PLANNING ONCOLOGY CLINICAL 
TRIALS  
Foley KA1, Hansen LG2 
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Northwood, NH, USA  
OBJECTIVES: To understand the value of quickly estimating the impact of certain 
inclusion/exclusion criteria on a potential clinical trial population using real-
world administrative data. METHODS: Using the Treatment Pathways tool and 
data from an 8-year oncology subset of the 2004 – 2012 MarketScan®databases, 
we identified patients with castrate-resistant prostate cancer (CRPC) with at least 
six months of history. From these patients, we identified cohorts with definitive 
exclusions (brain metastasis or other primary cancer) and time-dependent 
exclusions (based on radiation or treatments). Seven of 12 exclusion criteria were 
identifiable within the claims database. RESULTS: Inclusion criteria identified 
2,329 patients with CRPC based on two prostate cancer diagnoses, medical or 
surgical castration and receipt of docetaxel. Of them, 1370 (59%) had 6 months of 
follow-up data for evaluation of exclusion criteria. Among the 1370 patients, 248 
(18%) met none of the exclusion criteria, while 482 patients (35%) had brain 
metastasis and/or other cancers. The remaining 640 (47%) had at least one time-
dependent exclusion, including 534 receiving corticosteroids, 136 receiving 
androgen receptor and reductase inhibitors, 86 receiving radiation and 31 with 
ketoconazole. These patients could be trial-eligible depending on the timing of 
treatment cessation and trial recruitment. CONCLUSIONS: This study 
demonstrates a method to understand the impact of specific inclusion/exclusion 
criteria on a potential clinical trial population in just a few hours using an online 
pathway creation tool and administrative data representing millions of patients. 
Using this method, trial planners can evaluate different scenarios to quickly and 
easily determine estimated attrition rates helping them to maximize potential 
recruitment success. Limitations exist due to the timing of exclusions and data 
on lab results included in the exclusion criteria that were unavailable in this 
subset of claims data.  
 
PRM214  
USE OF A NOVEL ADJUNCTIVE CLINICAL TRIAL DESIGN TO EXAMINE 
EFFICACY, SAFETY OF ARMODAFINIL FOR THE TREATMENT OF BIPOLAR I 
DEPRESSION  
Calabrese JR1, Ketter TA2, Yang R3, Frye MA4 
1University Hospitals Case Medical Center, Cleveland, OH, USA, 2Stanford University School of 
Medicine, Stanford, CA, USA, 3Teva Pharmaceutical Industries Ltd., Frazer, PA, USA, 4Mayo 
Clinic, Rochester, MN, USA  
OBJECTIVES: Patients in randomized, controlled trials of bipolar depression are 
generally not representative of a clinical population. This study attempted to 
examine a large sample of patients more representative of patients seen in 
clinical practice. This report presents baseline patient characteristics from a 
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Phase 3 study examining adjunctive armodafinil for the treatment of a major 
depressive episode associated with bipolar I disorder (NCT01072929). METHODS: 
To assess the safety and efficacy of adjunctive armodafinil 150 mg/day in a 
heterogeneous sample of patients, this 8-week, double-blind, placebo-controlled, 
multicenter study evaluated adult patients with bipolar I disorder who were 
currently experiencing a major depressive episode while taking 1-2 maintenance 
therapies (mood stabilizers and/or second-generation antipsychotics). RESULTS: 
The study was conducted at 70 centers in 10 countries from January 2010 to 
March 2012. Of 786 patients screened, 433 were randomized. Baseline disease 
severity as assessed by mean (SD) IDS-C30 total scores was characteristic of 
moderate depression (43.6 [6.93] and 43.2 [7.76] for the placebo and 150 mg 
groups, respectively). The most common concomitant treatments were 
valproate, lithium, and lamotrigine. Patients in the placebo and armodafinil 150 
mg groups experienced their first depressive episode 13.8 (SD 10.24) and 14.5 (SD 
11.73) years prior to screening, respectively. The number of distinct regimens of 
adjunctive treatments will also be reported. CONCLUSIONS: Because the design 
allowed a wider range of adjunctive maintenance therapies, subjects enrolled in 
this study may be more representative of patients in clinical practice. The 
diversity of therapeutic regimens encountered in this study may improve 
external validity/generalizability without sacrificing assay sensitivity, although a 
large sample size was necessary. Further studies are needed to explore how 
research on bipolar depression treatments can improve external validity by 
employing more inclusive designs without sacrificing assay sensitivity.  
 
PRM215  
INVESTIGATOR-INITIATED APPROACH TO ADDRESS AN OPTIMIZATION 
PROBLEM IN DESIGNING COST-EFFICIENT STUDIES  
Huynh L1, Clark M2, Frick KD3 
1Analysis Group, Boston, MA, USA, 2Brown University, Providence, RI, USA, 3Johns Hopkins 
Bloomberg School of Public Health, Baltimore, MD, USA  
OBJECTIVES: To improve research productivity in an economic environment 
with limited resources, researchers may need to consider investigator-initiated 
approaches to design cost-efficient studies. A cost function was developed to 
guide decisions about trade-offs to be made in clinical trial design with the 
objective of minimizing cost while achieving a given level of power to detect 
differences in patient-reported outcomes. METHODS: The design and conduct of 
a clinical study was treated as a constrained optimization problem. A cost 
function was developed, a Lagrangian function was constructed, and first-order 
partial derivatives were taken with respect to each choice variable (e.g., number 
of recruitment sites, number of follow-up visits, and study duration). 
Comparative statics analysis was used to examine the changes in the choice 
variables as a result of changes in the exogenous variables. RESULTS: A 
necessary condition to minimize cost while achieving a given power is the 
equivalence of the ratios of the marginal cost associated with increasing each 
choice variable and the marginal change in power associated with each choice 
variable; in other words the same cost per unit of output created by each input at 
the margin. For second-order condition, we made the reasonable assumption 
that increasing the number of participants recruited leads to a decrease in the 
marginal rate of change in the Type II error which holds. Comparative statics 
analysis showed that the increase or decrease in the rate of recruitment, 
expected percent loss to follow-up, and the cost of interventions lead to different 
trade-offs between the marginal cost of conducting the clinical trial and the 
marginal change in the probability of committing a Type II error. CONCLUSIONS: 
In light of funding challenges, researchers could consider the trade-offs required 
to achieve a cost-efficient study for a given level of power using methods from 
economics and optimization.  
 
PRM216  
MULTI-NATIONAL RETROSPECTIVE CHART REVIEW STUDIES: LESSONS 
LEARNED FROM APPLICATION OF METHODOLOGY TO INTERNATIONAL 
EVALUATIONS OF BURDEN OF ILLNESS AND DRUG UTILIZATION AND  
SAFETY  
Payne KA1, Stein D1, Stemhagen A2 
1United BioSource Corporation, Dorval, QC, Canada, 2United BioSource Corporation, Blue Bell, PA, 
USA  
OBJECTIVES: In the absence of suitable health care databases, chart review 
studies can result in tailored datasets suitable for evaluations of burden of 
illness, unmet need and drug utilization and safety. This methodology, however, 
is associated with significant design and operational challenges. METHODS: 
Design and operational parameters of ten recent chart review studies of 
treatment patterns, resource utilization and costs of care, clinical outcomes 
and/or drug utilization and safety conducted in Canada, the United States, and 
western Europe have been summarized. Opportunities, challenges and lessons 
learned have been delineated in detail. RESULTS: Four of these studies were 
categorized as post authorization safety studies, and all but one of these studies 
was mandated by the FDA or EMA. Six of the 10 studies were in oncology, and 
evaluated outcomes in patients who had failed at least one line of 
chemotherapy. Sample size varied from 20 patients to greater than 2000, and the 
number of countries and sites varied from 1-6 and 4 to 375 respectively. Across 
studies, key challenges included delineation of eligibility and study periods that 
permit evaluations of recent care patterns yet allow for sufficient follow-up time; 
design and local implementation of case ascertainment and sampling frame 
methodologies; and safety reporting in the context of retrospective source data. 
Drug utilization studies evaluating inappropriate or off-label use required careful 
attention to protocol language to minimize response bias, as well as a carefully 
executed operational plan for the identification of prescribers and the collection 
of data from prescribers over time. CONCLUSIONS: Though challenging to 
implement, retrospective chart reviews are frequently necessary to address 
research questions spanning burden and costs of care to drug utilization and 
safety. A series of national and multi-national chart review case studies with 
diverse research objectives highlight common design and operational challenges 
that can be anticipated and overcome.  
 
PRM217  
TIME AND MOTION STUDY DESIGN: HANDLING VARIABILITY AND 
CONFOUNDING OF RESULTS  
Yeomans K1, Payne KA1, Pan YI1, De Cock E2 
1United BioSource Corporation, Dorval, QC, Canada, 2United BioSource Corporation, Barcelona, 
Spain  
Time and Motion (T&M) studies quantify time-related outcomes. Any given 
intervention process can be broken down into a set of pre-defined tasks for 
repeated observations, allowing estimation of the mean task durations in 
support of health economic analyses. While aiming to achieve robust estimates, 
variability in time measurements remains a main methodological challenge. 
OBJECTIVES: To discuss the importance of handling variability and confounding 
in T&M studies. METHODS: Investigation of the impact of variability on process 
duration begins with the analysis of process flow predictors and particularly the 
identification of potential confounders of process duration. Process-related 
variability can result from differences between countries or centers  
(e.g., geography, institution type) or within centers (e.g., patient characteristics, 
process specifics). Additional variability in time measurements can be due to 
insufficient delineation of tasks and inter-rater differences. RESULTS: Once 
potential sources of variability are identified, it must be decided whether  
a variable is to be minimized or accounted for in the study design relating back 
to the health economics objective of the T&M study. For instance, clear 
delineation of processes to be observed and thorough training help limit  
inter-rater variability. On the other hand, limiting data collection to a 
homogenous sample of centers and patients (i.e., specific patient and process 
characteristics), while minimizing variability in study setting and population, 
can compromise generalizability of the results. In situations where a medical 
intervention can be used to treat a broad range of patient populations with 
distinct clinical characteristics, limiting data collection to a certain subgroup 
means generating results applicable to these patients only. CONCLUSIONS: 
Variability can be controlled through thoughtful study design. However, 
significant confounders should be identified and accounted for to produce valid 
process time estimation. Proper handling of variability in time measurement will 
improve precision of the duration estimates in support of health economic 
analyses.  
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THE CHALLENGE OF EVIDENCE SYNTHESIS WITH SPARSE OR RARE EVENTS: 
HOW BAYES CAN HELP?  
Amzal B1, Nikodem M2 
1LA-SER Analytica, London, UK, 2CASPolska, Myslenice, Poland  
BACKGROUND: With the emergence of systematic reviews for evidence-based 
evaluations in health care, the quantitative methods to synthesize evidence have 
been increasingly developed and used to support decision making Particularly in 
the context of HTA evaluations where both post-marketing and pre-marketing 
data may be considered, the evidence to be synthesized can be sparse or related 
to rare outcomes such as risk outcomes. The Bayesian option has increasingly 
appeared as an unrivalled option for such challenging evidence synthesis cases. 
OBJECTIVES: This work aims at highlighting the strengths and limitations of 
Bayesian meta-analysis and mixed treatment comparisons and at providing 
guidance to doers and users of such evidence syntheses in the context of health 
technology assessment with rare or sparse health outcomes in the real-world 
setting. METHODS: Through a list of case studies in risk or benefit/risk studies 
and simulation-based comparisons, the state-of-the-art Bayesian meta-analytic 
approaches are reviewed, adapted to the context of rare events and evaluated for 
their robustness. Under-reporting of risk outcomes in post-marketing studies is 
accounted for in the Bayesian models and sensitivity to the choice of priors is 
analyzed. RESULTS: Provided thorough validation procedures and careful model 
and prior calibration, the Bayesian framework offers an unrivalled framework for 
evidence synthesis of scarce data, for both direct and indirect comparisons, with 
fair and robust quantification of uncertainty. CONCLUSION: Guidance can be 
derived based on the nature and quantity of data which do impact the methods 
reliability, in order to help practitioners and decision makers in using Bayesian 




THE VALUE OF A GOOD DECISION: ASSESSING THE ECONOMIC BENEFITS OF 
DECISION AIDS  
Butt T1, Findl O2, Orr S1, Rubin G1 
1University College London, London, UK, 2Hanusch Hospital, Vienna, Austria  
Decision aids are increasingly used to support doctors and patients in shared 
health care decision making, yet methods to measure their benefits for economic 
evaluation have received limited attention. Significant non-health benefits such 
as improved patient knowledge, experience and satisfaction may accrue through 
the use of decision aids. These cannot be assessed within the dominant health 
economic framework of cost utility analysis. The objective of this paper is to 
propose a new opportunity cost-based method suitable for assessing the benefits 
of decision aids relative to other interventions in a resource-constrained health 
care system. A literature review to identify how decision aids have been 
evaluated found that economic evaluations are limited. Non-health benefits 
